CELG Technical Analysis
As of date:11/20/2019
CELG stock price:108.24
CELG 50 DMA:103.23
CELG 200 DMA:95.60
CELG MACD (200-50):-7.63
CELG RSI:51.63
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)51.63
Extremely
Oversold

Also see:
CELG Market Cap History
CELG Shares Outstanding History
CELG YTD Return

Quotes delayed 20 minutes
Get Free SEC filing alerts for CELG:
CELG SEC Filing Email Alerts ServiceExternal link

NI Holdings (NODK) Shares Cross Above 200 DMA
54 minutes ago


Bullish Two Hundred Day Moving Average Cross - VGR
1 hour, 21 minutes ago


FYX Crosses Above Key Moving Average Level
1 hour, 21 minutes ago


Bullish Two Hundred Day Moving Average Cross - WHR
1 hour, 22 minutes ago


Realogy Holdings Breaks Above 200-Day Moving Average - Bullish for RLGY
1 hour, 22 minutes ago


RMAX Crosses Above Key Moving Average Level
1 hour, 22 minutes ago


Colfax (CFX) Shares Cross Above 200 DMA
1 hour, 22 minutes ago


CBT Makes Bullish Cross Above Critical Moving Average
1 hour, 22 minutes ago


iShares S&P Small-Cap 600 Growth (IJT) Shares Cross Above 200 DMA
1 hour, 22 minutes ago


Charles Schwab Breaks Above 200-Day Moving Average - Bullish for SCHW
1 hour, 23 minutes ago


Alamo Group (ALG) Shares Cross Above 200 DMA
1 hour, 24 minutes ago


COWZ Crosses Above Key Moving Average Level
1 hour, 24 minutes ago


Bullish Two Hundred Day Moving Average Cross - TEO
1 hour, 24 minutes ago


MYE Makes Bullish Cross Above Critical Moving Average
1 hour, 24 minutes ago


IEUR Crosses Above Key Moving Average Level
1 hour, 24 minutes ago


More Technical Analysis News

CELG Technical AnalysisCELG RSI
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold worldwide, primarily to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities and the medical profession. Co. manufactures products in the United States and Puerto Rico and has manufacturing operations in two foreign countries. Co. has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics.

When researching a stock like Celgene, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from CELG Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for CELG stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
CELG DMACELG MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Celgene (CELG) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

CNC Technical Analysis
COO Technical Analysis
DGX Technical Analysis
DHR Technical Analysis
DVA Technical Analysis
EW Technical Analysis
GILD Technical Analysis
HCA Technical Analysis
HOLX Technical Analysis
HSIC Technical Analysis
More Healthcare companies »

 

CELG Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2020, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.